Skip to main content

Table 2 Multivariate analysis using step-wise method

From: Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein–Barr virus DNA level and tumor response to palliative chemotherapy

Characteristic HR 95% CI P-value
EBV DNA level 2.13 1.58–2.88 < 0.001
Tumor response 1.34 1.02–1.77 0.036
N stage 1.40 1.02–1.91 0.036
Metastatic site
 Lung vs. Bone 0.89 0.58–1.36 0.589
 Liver vs. Bone 1.00 0.66–1.51 0.993
 Distant nodal vs. Bone 0.98 0.52–1.84 0.956
 Multiple vs. Bone 2.39 1.77–3.23 < 0.001
LRRT 0.76 0.59–0.98 0.037
  1. All factors were involved in the analysis and five factors remained
  2. Abbreviations: EBV Epstein-Barr virus, HR hazard ratio, CI confidence interval, LRRT locoregional radiotherapy
  3. All potential prognostic factors were involved in the analysis and five factors remained
  4. HRs were calculated for N stage (N2–3 vs. N0–1); LRRT (Yes vs. No); EBV DNA level (Detectable vs. Undetectable) and Tumor response (SD/PD vs. CR/PR)
\